Sign In
Buy PLX
$1.96
-0.0300 (-1.51%)
At Close: Jun 03, 2026
This press release is intended for US audiences for transparency relative to global news for the Fabry community. This dosing regimen for Elfabrio is not approved in the US. In the US, the FDA-approve
Reviewing Protalix BioTherapeutics (NYSE:PLX) & JATT Acquisition (NYSE:JATT)
01:50am, Thursday, 05'th Feb 2026
Protalix BioTherapeutics (NYSE: PLX - Get Free Report) and JATT Acquisition (NYSE: JATT - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast th
Oral presentation provides additional scientific rationale on Krabbe disease, one of four LSDs in the Phase 2 SOTERIA basket trial designed to evaluate the safety and clinical activity of lead drug ca
A March Decision That Could Change Protalix BioTherapeutics Outlook
09:27pm, Sunday, 01'st Feb 2026
Protalix Bio Therapeutics (PLX) received a positive CHMP opinion for Elfabrio's every-four-weeks dosing in stable adult Fabry patients, pending EC approval by March. PLX's Elfabrio could halve infusio
Protalix wins EU panel backing for expanded dosing of Fabry disease drug
10:20am, Friday, 30'th Jan 2026
Protalix Biotherapeutics Inc (NYSE-A:PLX, FRA:PBDA) said on Friday that the European Medicines Agency's human medicines committee has issued a positive opinion recommending approval of an expanded dos
Committee for Medicinal Products for Human Use (CHMP) issues a positive opinion following re-examination, which will be reviewed by the European Commission (EC), with a decision anticipated by March 2
Committee for Medicinal Products for Human Use (CHMP) issues a positive opinion following re-examination, which will be reviewed by the European Commission (EC), with a decision anticipated by March 2
Nasdaq leads losses as investors juggle earnings, Fed Chair nomination
07:04am, Friday, 30'th Jan 2026
12:00pm: Apple faces challenges ahead Analysts view Apple’s near-term growth as strong, led by iPhone and Services, but longer-term margin sustainability...
Protalix wins EU panel backing for expanded dosing of Fabry disease drug
05:19am, Friday, 30'th Jan 2026
Protalix Biotherapeutics Inc (NYSE-A:PLX, FRA:PBDA) said on Friday that the European Medicines Agency’s human medicines committee has issued a positive...
Protalix BioTherapeutics CEO outlines 2026 priorities, highlights progress across clinical pipeline
08:41am, Monday, 05'th Jan 2026
Protalix Biotherapeutics Inc (NYSE-A:PLX) on Monday shared an update from its CEO Dror Bashan, who highlighted the company's strategic priorities for 2026, with a focus on advancing its clinical pipel
Protalix BioTherapeutics Letter to Stockholders
06:50am, Monday, 05'th Jan 2026
CARMIEL, Israel, Jan. 5, 2026 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production and commercialization o
Micron shares jump after strong Q1 earnings, robust outlook
11:31am, Wednesday, 17'th Dec 2025
Micron Technology Inc (NASDAQ:MU) on Wednesday posted stronger-than-expected fiscal first-quarter results and forecast robust growth for the next quarter,...
Protalix BioTherapeutics partners with Secarna Pharmaceuticals on rare kidney disease drug development
08:41am, Wednesday, 17'th Dec 2025
Protalix Biotherapeutics Inc (NYSE-A:PLX) announced that it has entered into a collaboration and option agreement with Secarna Pharmaceuticals to jointly develop new antisense oligonucleotide (ASO) th
Protalix Biotherapeutics and Secarna Pharmaceuticals Enter into Collaboration and Option Agreement
06:50am, Wednesday, 17'th Dec 2025
Partnership combines Protalix's rare disease and biologics expertise with Secarna's AI–powered OligoCreator® platform to jointly develop pharmaceutical candidates for rare renal indications Protali
Oracle shares slide as $10B Michigan data center faces funding uncertainty
06:03am, Wednesday, 17'th Dec 2025
Oracle Corp (NYSE:ORCL, XETRA:ORC) shares fell almost 6% on Wednesday morning after the Financial Times reported that its plans for a $10 billion data...
